Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year Low After Earnings Miss

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) reached a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $2.81 and last traded at $2.86, with a volume of 15100119 shares. The stock had previously closed at $5.37.

The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.22). The business had revenue of $190.70 million during the quarter, compared to analyst estimates of $206.03 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 15.47%. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.05 earnings per share.

Myriad Genetics News Roundup

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Management is implementing initiatives focused on improving efficiency, productivity and scalability. Myriad is also engaging with payers and pursuing revenue-cycle changes intended to make reimbursement more predictable and improve performance over time. Myriad Genetics second-quarter financial results
• Neutral Sentiment: On the earnings call, management discussed efforts to improve reimbursement, operating efficiency and the scalability of the business. Investors will likely look for evidence that these initiatives can stabilize revenue and margins in upcoming quarters. Myriad Genetics Q2 2026 earnings call transcript
• Negative Sentiment: Second-quarter revenue fell 11% year over year to $190.7 million, missing the $206.0 million consensus estimate. Volume declined 1%, while average revenue per test dropped 9%, indicating pressure on both demand and pricing or reimbursement. Myriad Genetics Q2 loss and revenue miss
• Negative Sentiment: Myriad reported a loss of $0.25 per share versus the expected loss of $0.03 and $0.05 earnings per share a year earlier. The company also posted an operating loss, a negative net margin and negative return on equity, highlighting continued profitability challenges.
• Negative Sentiment: Full-year 2026 revenue guidance was reduced to approximately $770 million-$790 million, well below the roughly $862.7 million analyst consensus. TD Cowen maintained a Hold rating but lowered its price target to $4, reflecting diminished near-term expectations. TD Cowen rating and price target

Analysts Set New Price Targets

MYGN has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. TD Cowen decreased their price objective on shares of Myriad Genetics from $6.00 to $4.00 and set a “hold” rating on the stock in a report on Friday. Finally, Weiss Ratings lowered shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Insider Buying and Selling

In related news, Director Rashmi Kumar sold 15,000 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $4.46, for a total value of $66,900.00. Following the completion of the transaction, the director directly owned 171,889 shares of the company’s stock, valued at approximately $766,624.94. This represents a 8.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul Bisaro acquired 7,500 shares of Myriad Genetics stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average cost of $3.69 per share, with a total value of $27,675.00. Following the completion of the purchase, the director owned 97,441 shares in the company, valued at $359,557.29. The trade was a 8.34% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Myriad Genetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in shares of Myriad Genetics by 2,333.3% during the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after buying an additional 4,480 shares in the last quarter. Quarry LP lifted its stake in shares of Myriad Genetics by 155.6% in the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after buying an additional 2,657 shares in the last quarter. Royal Bank of Canada boosted its position in Myriad Genetics by 129.6% during the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock worth $31,000 after acquiring an additional 2,818 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Myriad Genetics during the second quarter worth about $37,000. Finally, American Century Companies Inc. purchased a new stake in Myriad Genetics during the 2nd quarter valued at about $55,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics Stock Performance

The company has a market cap of $270.13 million, a PE ratio of -2.40 and a beta of 1.64. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.19 and a current ratio of 2.40. The firm’s 50 day moving average is $5.11 and its 200-day moving average is $4.95.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.